Αποτελέσματα Αναζήτησης
1 Αυγ 2013 · Although there is strong evidence for the use of aspirin for secondary prevention of CVD (as noted in the 2013 ADA Standards of Care), aspirin use for primary prevention of CVD in patients with and without diabetes is less clear cut in light of the potential risks of therapy.
The randomized experiment ASCEND (Study of Cardiovascular Events in Diabetes) provides encouraging results on the effects of low-dose aspirin for the prevention of serious vascular events in adults with diabetes; however, the results of this trial was not encouraging as an increased risk of gastrointestinal and extracranial bleeding events were ...
26 Αυγ 2018 · We performed the ASCEND (A Study of Cardiovascular Events in Diabetes) randomized trial to assess the efficacy and safety of enteric-coated aspirin at a dose of 100 mg daily, as compared with...
Aspirin is the cornerstone of treatment in patients with cardiovascular disease, irrespective of diabetes status, being able to confer a 19% relative risk reduction per year in serious vascular events compared with placebo at long-term follow-up (6.7% vs 8.2% per year, p < 0.0001).
15 Δεκ 2010 · Low-dose aspirin therapy is reasonable in adults with diabetes and no history of vascular disease, whose 10-year risk of CHD events is greater than 10 percent, and who are not at increased risk...
1 Ιαν 2003 · In addition to treating the primary cardiovascular risk factor(s) identified, consider aspirin therapy as a primary prevention strategy in high-risk men and women with type 1 or type 2 diabetes. This includes diabetic subjects with the following:
27 Μαΐ 2010 · Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.
